Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Giorgio Scagliotti

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Share this video  
Similar topics
Related videos
4:01
Stereotactic body radiotherapy (SBRT) in NSCLC
Matthias Guckenberger
2:44
Tackling urgent questions in EGFRm NSCLC
Nicolas Girard
0:56
Pembrolizumab and the significance of PD-L1 for lung cancer
Roy Herbst
2:05
ASSESS trial: Blood test for EGFR mutation in advanced non-small cell lung cancer
2:04
Biomarker testing in NSCLC
Keith Kerr
Lung Cancer
Docetaxel, Ramucirumab
ECC 2015
Interview
26th September 2015
More from Giorgio Scagliotti
Immunotherapy in NSCLC: a perspective
The importance of precision immunotherapy: cost, benefit & toxicity
Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals